{"slug":"cll","tag":"cll","variants":["cll"],"description":"No description yet","count":9,"kinds":{"person":9},"related":[{"slug":"btk","tag":"btk","shared":4},{"slug":"venetoclax","tag":"venetoclax","shared":3},{"slug":"australia","tag":"australia","shared":2},{"slug":"fixed-duration","tag":"fixed-duration","shared":2},{"slug":"guidelines","tag":"guidelines","shared":2},{"slug":"alliance","tag":"alliance","shared":1},{"slug":"mrd","tag":"mrd","shared":1},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":1},{"slug":"trialist","tag":"trialist","shared":1},{"slug":"uk","tag":"uk","shared":1}],"records":[{"id":"john-byrd","kind":"person","name":"John C. Byrd","route":"/people/john-byrd/","tldr":"Led the ibrutinib trials that turned CLL from a chemotherapy disease into one treated with pills."},{"id":"jennifer-woyach","kind":"person","name":"Jennifer A. Woyach","route":"/people/jennifer-woyach/","tldr":"Led Alliance A041202, which showed ibrutinib beats chemoimmunotherapy in older CLL patients, and discovered BTK C481S resistance."},{"id":"jennifer-brown","kind":"person","name":"Jennifer R. Brown","route":"/people/jennifer-brown/","tldr":"Led ALPINE, the first head-to-head trial in which a next-generation BTK inhibitor (zanubrutinib) beat ibrutinib."},{"id":"kirsten-fischer","kind":"person","name":"Kirsten Fischer","route":"/people/kirsten-fischer/","tldr":"Led CLL14, which established one year of venetoclax plus obinutuzumab as a fixed-duration, chemotherapy-free CLL treatment."},{"id":"barbara-eichhorst","kind":"person","name":"Barbara Eichhorst","route":"/people/barbara-eichhorst/","tldr":"Led CLL13 (GAIA), showing venetoclax-based fixed-duration therapy beats chemoimmunotherapy in fit CLL patients."},{"id":"peter-hillmen","kind":"person","name":"Peter Hillmen","route":"/people/peter-hillmen/","tldr":"Led FLAIR, the UK trial showing MRD-guided ibrutinib plus venetoclax outperforms chemoimmunotherapy in CLL."},{"id":"john-seymour","kind":"person","name":"John F. Seymour","route":"/people/john-seymour/","tldr":"Led MURANO, which established venetoclax plus rituximab as fixed-duration therapy for relapsed CLL."},{"id":"william-wierda","kind":"person","name":"William G. Wierda","route":"/people/william-wierda/","tldr":"Led CAPTIVATE, which established fixed-duration ibrutinib plus venetoclax as a first-line option for CLL."},{"id":"constantine-tam","kind":"person","name":"Constantine S. Tam","route":"/people/constantine-tam/","tldr":"Led the zanubrutinib SEQUOIA trial and the first ibrutinib-venetoclax study in mantle cell lymphoma."}]}